Study population
Subjects were Japanese males aged between ≥ 20 and < 46 years,
with a body mass index between ≥ 18.5 and < 25.0 kg
m-2. Eligible subjects had no clinically problematic
abnormalities regarding their medical findings, physiological
examinations, and laboratory tests, and the investigator determined that
there were no problems that would have prevented participation in this
study. The following subjects were excluded: those who had a previous or
current medical history of functional disorders related to the liver,
heart, kidney, lungs, blood, gastrointestinal tract, or any other
disorders that would preclude participation; a previous or current
medical history of upper gastrointestinal disorders; a history of drug
allergy; white blood cell count ≤ 4000
µL-1;
neurological symptoms; a previous or current medical history of serious
infectious diseases, including opportunistic infections within 1 year
prior to administration of the drug; ingestion of grapefruit, grapefruit
juice or foods containing these ingredients within 8 days prior to the
start of administration of the study drug; or ingestion of St. John’s
Wort or foods containing these ingredients within 15 days prior to the
start of administration of the study drug.